Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Share-based Compensation (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Share-based Compensation for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 43.73% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 80.6% year-over-year, with the annual reading at $5.5 million for FY2025, 74.15% up from the prior year.
  • Share-based Compensation hit $1.1 million in Q4 2025 for Eton Pharmaceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.1 million in Q2 2025 to a low of $673000.0 in Q1 2021.
  • Historically, Share-based Compensation has averaged $960650.0 across 5 years, with a median of $867500.0 in 2021.
  • Biggest five-year swings in Share-based Compensation: plummeted 46.31% in 2023 and later skyrocketed 188.31% in 2025.
  • Year by year, Share-based Compensation stood at $863000.0 in 2021, then rose by 2.67% to $886000.0 in 2022, then decreased by 15.35% to $750000.0 in 2023, then rose by 4.27% to $782000.0 in 2024, then skyrocketed by 43.73% to $1.1 million in 2025.
  • Business Quant data shows Share-based Compensation for ETON at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $2.1 million in Q2 2025.